Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Evogene Ltd. EVGN

Healthcare  —  Biotechnology
0.42 0.00 0.00% as of 25 Sep
Market cap
$6.3M
P/E
0.0×
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Evogene Ltd. (EVGN) Business Profile

Updated before January 2025

Company Overview

Evogene Ltd. (NASDAQ: EVGN) is a leading computational biology company that leverages its proprietary AI-driven technology to revolutionize life sciences. Founded in 2002, the company is headquartered in Rehovot, Israel. Evogene was initially a division of Compugen Ltd. before becoming an independent entity. The company is led by Ofer Haviv, who serves as the President and Chief Executive Officer. Under his leadership, Evogene has grown into a prominent player in the fields of agriculture, human health, and industrial applications, utilizing its cutting-edge computational predictive biology platform.

Core Business Segments

Evogene operates through several subsidiaries and focuses on three primary business segments:

1. Agriculture

Evogene’s agricultural division is dedicated to improving crop productivity and sustainability. The company develops innovative solutions for crop protection, seed traits, and microbiome-based products. Key offerings include:

  • AgPlenus: Focused on developing next-generation crop protection products, including herbicides, fungicides, and insecticides.
  • Biomica: Specializes in microbiome-based solutions to enhance plant health and yield.

2. Human Health

Evogene has expanded its expertise into human health, leveraging its computational biology platform to develop microbiome-based therapeutics and other health-related solutions. Key subsidiaries include:

  • Biomica: Develops microbiome-based therapeutics for conditions such as inflammatory bowel disease (IBD), oncology, and immune-related disorders.
  • Canonic: Focuses on medical cannabis products, utilizing computational biology to optimize cannabis strains for therapeutic purposes.

3. Industrial Applications

Evogene’s industrial division applies its technology to develop sustainable solutions for industrial challenges. Key initiatives include:

  • Lavie Bio: Develops microbiome-based agricultural products to improve crop resilience and reduce environmental impact.
  • Corteva Collaboration: A partnership aimed at developing innovative seed traits and crop protection solutions.

Business Model

Evogene’s business model revolves around its proprietary Computational Predictive Biology (CPB) platform. This AI-driven platform integrates big data, machine learning, and computational biology to accelerate the discovery and development of novel products. The company generates revenue through:

  • Licensing agreements with agricultural and pharmaceutical companies.
  • Collaborative partnerships for product development.
  • Direct sales of its proprietary products and solutions.

By combining its technological expertise with strategic partnerships, Evogene ensures a steady revenue stream while maintaining a focus on innovation.

Strategic Direction

Evogene is committed to driving innovation and sustainability across its core business segments. Key strategic goals include:

  • Expansion of Product Portfolio: Developing new microbiome-based solutions for agriculture and human health.
  • Sustainability Initiatives: Promoting environmentally friendly agricultural practices through its products.
  • Global Market Penetration: Expanding its presence in key markets, including North America, Europe, and Asia.
  • R&D Investments: Increasing investment in research and development to enhance its computational biology platform and discover new applications.

Competitive Landscape

Evogene operates in highly competitive markets, facing competition from both established players and emerging startups. Key competitors include:

  • Agriculture: Bayer CropScience, Syngenta, and Corteva Agriscience.
  • Human Health: Seres Therapeutics, Finch Therapeutics, and 4D Pharma.
  • Industrial Applications: Ginkgo Bioworks and Zymergen.

Despite the competition, Evogene’s proprietary technology and multidisciplinary approach provide a significant competitive edge.

Risk Factors

Evogene faces several risks that could impact its operations and financial performance:

  • Market Dependence: Reliance on the success of its products in competitive markets.
  • Regulatory Challenges: Navigating complex regulatory environments for agricultural and pharmaceutical products.
  • Supply Chain Disruptions: Potential disruptions in the supply chain for raw materials and distribution.
  • Technological Risks: Dependence on the continued advancement of its computational biology platform.

Recent Developments

Evogene has made significant strides in recent years, including:

  • Product Launches: Introduction of new microbiome-based agricultural and therapeutic products.
  • Partnerships: Collaboration with leading companies like Corteva Agriscience to accelerate product development.
  • Technological Advancements: Enhancements to its CPB platform to improve predictive accuracy and efficiency.
  • Global Expansion: Establishing a stronger presence in international markets through strategic partnerships and direct sales.

Investment Considerations

Investors considering Evogene should weigh the following factors:

Strengths

  • Proprietary AI-driven technology with diverse applications.
  • Strong pipeline of innovative products.
  • Strategic partnerships with industry leaders.
  • Focus on sustainability and environmental impact.

Risks

  • High dependence on R&D success and regulatory approvals.
  • Competitive pressures in core markets.
  • Potential financial volatility due to market uncertainties.

Conclusion

Evogene Ltd. is a pioneering company at the intersection of computational biology and life sciences. With its innovative technology, diverse product portfolio, and commitment to sustainability, Evogene is well-positioned for future growth. However, investors should carefully consider the associated risks and market dynamics before making investment decisions.